Results 171 to 180 of about 449,349 (233)
Some of the next articles are maybe not open access.
AAZTA: An Ideal Chelating Agent for the Development of 44Sc PET Imaging Agents
Angewandte Chemie International Edition, 2017AbstractUnprecedented fast and efficient complexation of ScIII was demonstrated with the chelating agent AAZTA (AAZTA=1,4‐bis(carboxymethyl)‐6‐[bis(carboxymethyl)]amino‐6‐methylperhydro‐1,4‐diazepine) under mild experimental conditions. The robustness of the 44Sc(AAZTA)− chelate and conjugated biomolecules thereof is further shown by in vivo PET ...
Gábor Nagy +13 more
openaire +5 more sources
Research progress of 18F labeled small molecule positron emission tomography (PET) imaging agents
European Journal of Medicinal Chemistry, 2020With the development of positron emission tomography (PET) technology, a variety of PET imaging agents labeled with radionuclide 18F have been developed and widely used in the diagnosis and treatment of various clinical diseases in recent years. For example, they have showed a great value of study in the field of tumor detection, tumor treatment and ...
Mingliang Zhang +3 more
openaire +3 more sources
Progress in Molecular Biology and Translational Science, 2019
Neuroinflammation is thought to play a key role in the development and progression of neurodegenerative diseases such as Alzheimer's disease. Positron emission tomography (PET) is an in vivo imaging technique capable of studying the biochemical processes which provide the molecular basis of disease.
Janssen, Bieneke, Mach, Robert H.
openaire +5 more sources
Neuroinflammation is thought to play a key role in the development and progression of neurodegenerative diseases such as Alzheimer's disease. Positron emission tomography (PET) is an in vivo imaging technique capable of studying the biochemical processes which provide the molecular basis of disease.
Janssen, Bieneke, Mach, Robert H.
openaire +5 more sources
PET Imaging Agents for Alzheimer’s Disease
2017In the past four decades, PET (positron emission tomography) imaging has been developed into a common diagnostic tool. After an i.v. injection of a small amount of radioactive probe, PET images are taken based on the decay of short-lived positron-emitting isotopes.
Seok Rye Choi +3 more
openaire +2 more sources
Recent Developments of the PET Imaging Agents for Metabotropic Glutamate Receptor Subtype 5
Current Topics in Medicinal Chemistry, 2007Glutamate is a major excitatory neurotransmitter in central nervous system (CNS) acting through ionotropic and G-protein coupled metabotropic glutamate receptors. Metabotropic glutamate receptor 5 (mGluR5), a subtype in the group I mGluRs, presents in high density in many brain regions (hippocampus, cortex and olfactory system).
Meixiang Yu
openaire +3 more sources
Radiolabelled Agents for PET Imaging of Tumor Hypoxia
Current Medicinal Chemistry, 2012Hypoxia has been observed in a variety of human tumor types and evaluating tumor hypoxia is important because it increases resistance to radiotherapy and chemotherapy by inducing proteomic change that allow the tumor cell to survive in their hypoxic environment.
H, Kurihara, N, Honda, Y, Kono, Y, Arai
openaire +2 more sources
PET imaging agents targeting macrophage surface receptors
Chinese Science Bulletin, 2019Inflammation is a defense reaction produced by the body to protect against pathogenic factors, whereas the persistent state of inflammation or excessive inflammatory response is the pathological basis of many afflictions. As the main type of activated inflammatory cells in the inflammatory environment, macrophages exert great influence on the outcome ...
Zhequan Fu +2 more
openaire +1 more source